Alligator Bioscience and Orion Corporation announce exercise of development option under their 2021 Immuno-oncology Research Collaboration and License Agreement May 18, 2023
Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Gen ADC Program in Oncology May 10, 2023
Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics May 10, 2023
Convergent Therapeutics Announces $90 Million Series A Financing to Advance the Clinical Development of Radiopharmaceuticals for the Treatment of Prostate Cancer and Other Solid Tumors May 10, 2023
ALX Oncology and Sanofi to Evaluate Evorpacept + SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma May 10, 2023
Algok Bio and BTG to Develop and Commercialize Idetrexed, a Clinical-Stage Folate Receptor-Targeted Oncology Drug May 10, 2023
Coeptis Therapeutics to Acquire Allogeneic Immuno-Oncology NK Platform in Ph 1 Trials from Deverra Therapeutics April 27, 2023
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients April 27, 2023
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology April 27, 2023
Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA in a Ph 1b Clinical Trial in Melanoma April 20, 2023
ESSA Pharma and Janssen to evaluate EPI-7386 in combination with apalutamide and abiraterone acetate plus prednisone in patients with prostate cancer April 20, 2023
CTRL Therapeutics Launches with $10M Seed Financing to Advance Next-Gen Cell Therapy Platform for the Treatment of Solid Tumors April 20, 2023
Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets April 12, 2023
Scorpion Therapeutics and Pierre Fabre to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFRm NSCLC April 12, 2023
Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications April 12, 2023
Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Combinatorial IO Treatment Strategies April 6, 2023
Omega Enters Supply Agreement With Roche To Evaluate OTX-2002 – Atezolizumab combination in HCC April 6, 2023
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates April 6, 2023
Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights March 31, 2023
